These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 25541689)

  • 1. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis.
    Wong CC; Au SL; Tse AP; Xu IM; Lai RK; Chiu DK; Wei LL; Fan DN; Tsang FH; Lo RC; Wong CM; Ng IO
    PLoS One; 2014; 9(12):e115036. PubMed ID: 25541689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
    Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
    Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LNCAROD enhances hepatocellular carcinoma malignancy by activating glycolysis through induction of pyruvate kinase isoform PKM2.
    Jia G; Wang Y; Lin C; Lai S; Dai H; Wang Z; Dai L; Su H; Song Y; Zhang N; Feng Y; Tang B
    J Exp Clin Cancer Res; 2021 Sep; 40(1):299. PubMed ID: 34551796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.
    Xu Q; Tu J; Dou C; Zhang J; Yang L; Liu X; Lei K; Liu Z; Wang Y; Li L; Bao H; Wang J; Tu K
    Mol Cancer; 2017 Dec; 16(1):178. PubMed ID: 29262861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oviductus ranae protein hydrolysate (ORPH) inhibits the growth, metastasis and glycolysis of HCC by targeting miR-491-5p/PKM2 axis.
    Xu Q; Dou C; Liu X; Yang L; Ni C; Wang J; Guo Y; Yang W; Tong X; Huang D
    Biomed Pharmacother; 2018 Nov; 107():1692-1704. PubMed ID: 30257387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-4417 Targets Tripartite Motif-Containing 35 (TRIM35) and Regulates Pyruvate Kinase Muscle 2 (PKM2) Phosphorylation to Promote Proliferation and Suppress Apoptosis in Hepatocellular Carcinoma Cells.
    Song L; Zhang W; Chang Z; Pan Y; Zong H; Fan Q; Wang L
    Med Sci Monit; 2017 Apr; 23():1741-1750. PubMed ID: 28394882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma.
    Liu AM; Xu Z; Shek FH; Wong KF; Lee NP; Poon RT; Chen J; Luk JM
    PLoS One; 2014; 9(1):e86872. PubMed ID: 24466275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.
    Hu W; Lu SX; Li M; Zhang C; Liu LL; Fu J; Jin JT; Luo RZ; Zhang CZ; Yun JP
    Oncotarget; 2015 Mar; 6(9):6570-83. PubMed ID: 25788265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-122 affects cell aggressiveness and apoptosis by targeting PKM2 in human hepatocellular carcinoma.
    Xu Q; Zhang M; Tu J; Pang L; Cai W; Liu X
    Oncol Rep; 2015 Oct; 34(4):2054-64. PubMed ID: 26252254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2 induces apoptosis-resistance in hepatocellular carcinoma cells via the HIF-1α/PKM2 pathway.
    Wang Q; Lu D; Fan L; Li Y; Liu Y; Yu H; Wang H; Liu J; Sun G
    Int J Mol Med; 2019 Jan; 43(1):475-488. PubMed ID: 30365092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of miR-199a maturation by HuR is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma.
    Zhang LF; Lou JT; Lu MH; Gao C; Zhao S; Li B; Liang S; Li Y; Li D; Liu MF
    EMBO J; 2015 Nov; 34(21):2671-85. PubMed ID: 26346275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dauricine upregulates the chemosensitivity of hepatocellular carcinoma cells: Role of repressing glycolysis via miR-199a:HK2/PKM2 modulation.
    Li W; Qiu Y; Hao J; Zhao C; Deng X; Shu G
    Food Chem Toxicol; 2018 Nov; 121():156-165. PubMed ID: 30171973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of pyruvate kinase M2 isoform inhibits cell motility in hepatocellular carcinoma cells.
    Chen YL; Song JJ; Chen XC; Xu W; Zhi Q; Liu YP; Xu HZ; Pan JS; Ren JL; Guleng B
    World J Gastroenterol; 2015 Aug; 21(30):9093-102. PubMed ID: 26290635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma.
    Chen Z; Lu X; Wang Z; Jin G; Wang Q; Chen D; Chen T; Li J; Fan J; Cong W; Gao Q; He X
    Oncotarget; 2015 Feb; 6(4):2538-48. PubMed ID: 25576919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
    Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
    J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic signature genes associated with susceptibility to pyruvate kinase, muscle type 2 gene ablation in cancer cells.
    Jung Y; Jang YJ; Kang MH; Park YS; Oh SJ; Lee DC; Xie Z; Yoo HS; Park KC; Yeom YI
    Mol Cells; 2013 Apr; 35(4):335-41. PubMed ID: 23515579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma.
    Feng J; Wu L; Ji J; Chen K; Yu Q; Zhang J; Chen J; Mao Y; Wang F; Dai W; Xu L; Wu J; Guo C
    J Exp Clin Cancer Res; 2019 May; 38(1):204. PubMed ID: 31101057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.
    Chen D; Wang Y; Lu R; Jiang X; Chen X; Meng N; Chen M; Xie S; Yan GR
    Theranostics; 2020; 10(19):8558-8572. PubMed ID: 32754263
    [No Abstract]   [Full Text] [Related]  

  • 19. Enhanced expression of the M2 isoform of pyruvate kinase is involved in gastric cancer development by regulating cancer-specific metabolism.
    Shiroki T; Yokoyama M; Tanuma N; Maejima R; Tamai K; Yamaguchi K; Oikawa T; Noguchi T; Miura K; Fujiya T; Shima H; Sato I; Murata-Kamiya N; Hatakeyama M; Iijima K; Shimosegawa T; Satoh K
    Cancer Sci; 2017 May; 108(5):931-940. PubMed ID: 28235245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ectosomal PKM2 Promotes HCC by Inducing Macrophage Differentiation and Remodeling the Tumor Microenvironment.
    Hou PP; Luo LJ; Chen HZ; Chen QT; Bian XL; Wu SF; Zhou JX; Zhao WX; Liu JM; Wang XM; Zhang ZY; Yao LM; Chen Q; Zhou D; Wu Q
    Mol Cell; 2020 Jun; 78(6):1192-1206.e10. PubMed ID: 32470318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.